Cannabinoids for Osteoarthritis Pain Effectiveness Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Osteoarthritis of KneeOsteoarthritis Hip
Interventions
DRUG

CBD

The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

DRUG

THC

The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

DRUG

Placebo

The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.

Trial Locations (3)

M5G 2C4

University Health Network, Toronto

M5S 1B2

Women's College Hospital, Toronto

H3G 1A4

McGill University Health Centre/Montreal General Hospital, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University Health Network, Toronto

OTHER

NCT06878417 - Cannabinoids for Osteoarthritis Pain Effectiveness Trial | Biotech Hunter | Biotech Hunter